Background: Cancerous cells usually exhibit increased aerobic glycolysis, compared with normal tissue (the Warburg effect), making this pathway an attractive therapeutic target.
A change in cellular bioenergetics, resulting in elevated metabolism and a switch towards aerobic glycolysis, is recognised as a hallmark of cancer and is correlated with tumour progression and drug resistance (Vander Heiden et al, 2009; Cairns et al, 2011; Chen, 2012) . These metabolic changes promote nutrient uptake (Vander Heiden et al, 2009) , overcome poor tissue oxygen supply and increased oxidative stress (Enns and Ladiges, 2012) , resist apoptosis (Kroemer and Pouyssegur, 2008) , and promote metastasis (Chen, 2012) . This has led to an interest in targeting tumour metabolism for anticancer therapies, either by itself (Pelicano et al, 2006; Cuperlovic-Culf et al, 2012; Zhang and Yang, 2013) , or in combination with radiotherapy (Coleman et al, 2008) , or chemotherapy (Hernlund et al, 2008; Calvino et al, 2011) . Specifically, the glycolysis inhibitors 2-deoxyglucose (2DG) (Dwarakanath, 2009 ), lonidamine (Brawer, 2005 ) and 3-bromopyruvate (3Br) (Shoshan, 2012) have all been used in clinical anticancer therapies.
Each of these glycolysis inhibitors inactivates hexokinase II (Brawer, 2005; Pelicano et al, 2006; Moreno-Sanchez et al, 2007; Scatena et al, 2008; Shoshan, 2012) , although GAPDH is the preferred target of 3Br (Pereira da Silva et al, 2009) . The inhibitors cause rapid depletion of downstream metabolites such as NADPH, pyruvate, and ATP. This disrupts tumour metabolism-dependent antioxidant defences (Trachootham et al, 2009) , thereby elevating cytotoxic reactive oxygen species (ROS) (Kim et al, 2008; AykinBurns et al, 2009) . Additionally, glycolysis inhibitors impair energy-dependent DNA repair and cellular recovery processes (Dwarakanath, 2009) , cause cell cycle arrest (Qie et al, 2012) , and initiate apoptosis by inhibiting antiapoptotic Bcl-2 family members (Ravagnan et al, 1999; Zagorodna et al, 2012) . Finally, glycolysis inhibitors downregulate ABC transporters, thereby overcoming multidrug resistance (Wartenberg et al, 2010; Nakano et al, 2011) .
Photodynamic therapy (PDT) is an evolving but underused treatment for cancers of the head, neck, lung, pancreas, intra-peritoneal cavity, breast, prostate, and skin (Bown, 2012; Milla Sanabria et al, 2012) . Photodynamic therapy involves the photoactivation of a topically or systemically applied photosensitiser in the presence of oxygen, resulting in the formation of ROS, especially singlet oxygen, hydroxyl radicals, and peroxides (Milla Sanabria et al, 2012) . Photodynamic therapy-induced ROS cause lipid peroxidation, crosslinking of proteins and damage to multiple cellular sites, including: membranes, DNA, and cytoskeleton (Oleinick and Evans, 1998) . In addition, PDT shrinks tumour microvasculature and stimulates immune responses against the tumour (Mroz et al, 2010; Anand et al, 2012; Milla Sanabria et al, 2012) .
As an adjunctive treatment, PDT has previously been combined successfully with a number of chemotherapeutic drugs, pro-oxidant agents, angiogenesis inhibitors, and immunotherapy (Zuluaga and Lange, 2008; Anand et al, 2012; Diez et al, 2012) ; all of which demonstrated advantages over PDT alone. Photodynamic therapy is known to deplete ATP, due to mitochondrial damage, and this may be important for initiating cytotoxicity (Ji et al, 2010) . For this reason, metabolic inhibitors are a logical choice to supplement PDT. Studies of individual metabolic inhibitors: 2DG (Noodt et al, 1998; Dahle et al, 2001; Kirveliene et al, 2003) or lonidamine (Shevchuk et al, 1996) demonstrate potentiation of PDT cytotoxicity. However, there is no homogeneity in the existing data. Each study used different cell lines, different photosensitisers, and different light dose regimens. Without this direct comparison, there can be no sensible rationale for selecting the best glycolysis inhibitor to move forward clinically in combination with existing PDT. Crucially, no study has included a non-cancerous control cell type.
To resolve these questions, we have directly compared the three most promising clinical metabolic inhibitors (2DG, lonidamine and 3Br), in combination with the most widely used clinical photosensitiser, for their ability to potentiate PDT cytotoxicity in vitro, both in MCF-7 cancer cells and human mammary epithelial cells (HMEC) primary breast cells.
MATERIALS AND METHODS
Unless stated otherwise, all reagents were from Sigma-Aldrich (Poole, UK).
Glycolysis inhibitors. 3-Bromopyruvate and 2DG were kept refrigerated as solids. A stock 6 mM ethanolic solution of lonidamine was stored at À 20 1C.
Cell cultures. Human breast adenocarcinoma cell line MCF-7 was a gift of Dr Marilena Loizidou, UCL Medical School, London (Moreno-Sanchez et al, 2007) . MCF-7 cells were maintained as monolayers in RMPI 1640 medium supplemented with 100 mU ml À 1 streptomycin, 100 mU ml À 1 penicillin and 10% heat-inactivated fetal calf serum (FCS) at 37 1C in a humidified 5% CO 2 atmosphere.
Normal primary HMEC were from Gibco (Paisley, UK) and maintained in the supplier's proprietary serum-free medium with 1% HMEC supplement and 50 mg ml À 1 bovine pituitary extract. Cells were seeded in 24-well plates for 24 h before the start of each experiment (MCF-7: 200 000 cells per well; HMEC: 100 000 cells per well).
Photodynamic therapy treatment. All cell washes and incubations were carried out under subdued lighting. Cells were incubated for 3 h with 20 mg ml À 1 (120 mM) 5-aminolevulinic acid (ALA) in serum-free RPMI medium. In some experiments, cells were coincubated with ALA and glycolysis inhibitors. After ALA loading, cells were washed with PBS and maintained in phenol red-free RPMI plus 10% FCS, with or without glycolysis inhibitors, until the end of the experiment. Cells were exposed to between 5 and 30 J cm À 2 white light from a 500 W halogen bulb, heat-filtered through 5 cm of water.
Cell viability analysis. Cells were trypsinised and cell number was determined by counting in all nine major grid squares of a Neubauer Improved haemocytometer. Percentage cell death was determined by 20 mg ml À 1 propidium iodide (PI) flow cytometry (FACSCalibur, Beckton Dickinson, Oxford, UK) counting 10 000 gated cells per condition wherever possible (in some experiments, viability was so low that only B4000 cells could be counted). For each condition, the total numbers of live and dead cells were calculated by combining the percentage cell death and the cell number data. Apoptosis was assessed by annexin V-FITC/PI flow cytometry of 10 000 gated cells, according to the supplier's protocol (Miltenyi Biotech, Bisley, UK).
Clonogenic assay. Cells were treated with 10 J cm À 2 PDT (or dark controls) and incubated for 24 h with glycolysis inhibitors, as detailed above. Then, 1000 live cells per condition (calculated from cell viability analysis) were added to 3 ml RPMI þ 10% FCS in poly-lysine-coated six-well plates and cultured for 9 days in the absence of glycolysis inhibitors. Wells were stained with 0.5% w/v methylene blue in 50% ethanol. The number of total colonies (42 cells) and large colonies (450 cells) were counted per condition and photographed under identical lighting.
5-Aminolevulinic acid uptake. Cells were incubated for 5 h in 1 mM ALA plus glycolysis inhibitor, then washed with PBS and lysed with 5% SDS. The amount of protoporphyrin IX, formed from ALA, was monitored by fluorescence spectroscopy (ex 408 nm, em 600-740 nm; Fluoromax-P, HORIBA, Stanmore, UK).
Reactive oxygen species measurements. All ROS probes were from Invitrogen (Paisley, UK). ROS levels were assayed by incubating cells for 30 min with either 10 mM 2 0 ,7 0 -dichlorodihydrofluorescein diacetate (DCFHDA: a general ROS probe) or 10 mM dihydroethidium (DHE: a probe more sensitive to superoxides). After staining, cells were trypsinised and analysed by flow cytometry.
ATP assay. Cells were washed with PBS, then scraped into 100 ml ice cold 0.5% TCA plus 1% Triton X-100, followed by 400 ml 0.1 M Tris pH 7.4. The homogenate was centrifuged and 50 ml supernatant per condition aliquoted into a white 96-well plate. One-hundred microlitre Luciferase/Luciferin (ENLITEN, Promega, Southampton, UK) was added per well. Bioluminescence was measured at room temperature in a FLUOStar Optima plate reader (BMG Labtech, Aylesbury, UK) using 4 s integration per well.
Statistical analyses. Data were analysed by one-way ANOVA using GraphPad InStat 3.0a software (La Jolla, CA, USA). Within each category (dark or PDT) or within each time point, data were compared with the ALA-only control using Dunnett's multiple comparisons post-test. Between categories (dark vs PDT), data were compared using Bonferroni post-test. Differences were considered statistically significant at Po0.05. All values are reported as mean ± s.e.m.
RESULTS
Coincubation of ALA with glycolysis inhibitors counteracts PDT cytotoxicity. In initial dose-response assays, we coincubated MCF-7 cells for 3 h with ALA and a range of glycolysis inhibitor concentrations. Following 30 J cm À 2 PDT (or darkness), cells were incubated for 24 h in the presence of the same inhibitor concentration.
In the dark, only 30 mM 3Br produced a significant increase in percentage cell death (24%), compared with the no-drug control.
All of the other inhibitor concentrations produced o10% cell death in the dark ( Figure 1A , black bars). Photodynamic therapy with ALA alone demonstrated 50% cell death ( Figure 1A , white bar). Photodynamic therapy with 3Br demonstrated a dosedependent increase in percentage cell death up to 12 mM, above which percentage cell death decreased to the PDT control level. 2-Deoxyglucose and lonidamine both demonstrated dose-dependent decreases in percentage cell death following PDT, with 50 mM and 300 mM lonidamine both demonstrating a significant reduction in cell death compared with the PDT control ( Figure 1A) .
Analysis of total cell numbers ( Figure 1B ) produced a similar trend. Thus, PDT in the absence of glycolysis inhibitors caused a three-fold decrease in total cell number compared with the dark control. Photodynamic therapy in the presence of 3-12 mM 3Br demonstrated a small but insignificant decrease in live cell numbers compared with the PDT control. However, PDT with 30 mM 3Br was protective against PDT cytotoxicity and produced a significant increase in live cells and in total cell numbers compared with the PDT control. Similarly, a dose-dependent PDT protective effect was seen with 2DG and lonidamine. Importantly, the cell death-protective effect was PDT-specific; in the dark, each inhibitor demonstrated a dose-dependent decrease in live cells compared with the ALA-only control. These results were thus contradictory: by themselves, the inhibitors caused modest dose-dependent cell death, but when combined with PDT they dose-dependently reduced cell death.
Glycolysis inhibitors restrict ALA uptake. 5-Aminolevulinic acid is a pro-drug that must undergo several steps (cellular uptake, enzymatic processing) to generate the active protoporphyrin IX (ppIX) photosensitiser. Competing against this are cellular efflux pumps and enzymatic conversion of ppIX to photochemically inactive haeme. Any or all of these steps could be affected by glycolysis inhibitors, resulting in lower than expected levels of ppIX that could explain the dose-dependent decrease in PDT cytotoxicity. As ppIX has a well-defined fluorescence spectrum, we used fluorimetry to determine whether glycolysis inhibitors decrease intracellular levels of ppIX. Coincubating MCF-7 cells with ALA and glycolysis inhibitors for 5 h, resulted in large and significant decreases in intracellular ppIX accumulation (Supplementary Figure S1) . Shevchuk et al (1996) also found that lonidamine inhibited ppIX accumulation. 2-Deoxyglucose inhibits 14 [C]-labelled ALA uptake in WiDr colon cancer cells (Gederaas et al, 2001) and if this occurs with other glycolysis inhibitors, it could explain the lower ppIX accumulation.
Glycolysis inhibition after ALA loading strongly potentiates PDT cytotoxicity. In contrast to the PDT protective effect seen when cells were coincubated with ALA and glycolysis inhibitors, we found a robust increase in PDT-induced cytotoxicity (more than three-fold above ALA-only), at a range of light doses, when 180 mM 2DG or 300 mM lonidamine (but not 12 mM 3Br) was added after ALA loading (Figure 2A and B) . For these experiments, inhibitors were added 15 min before PDT and maintained for 24 h.
We next investigated how the duration of glycolysis inhibition affected PDT cytotoxicity at 24 h. Acute application of glycolysis inhibitors (for 1 h, 2 h, or 24 h) immediately after 10 J cm À 2 PDT yielded gradual increases in MCF-7 cytotoxicity with lonidamine. Conversely, 2DG was initially protective against PDT when applied for 1 or 2 h, but strongly potentiated PDT cytotoxicity if applied for 24 h ( Figure 2C and D) . In subsequent experiments, we added 180 mM 2DG or 300 mM lonidamine immediately after PDT for 24 h. We also settled on 10 J cm À 2 as our standard PDT light dose. As 12 mM 3Br had no PDT potentiating effect when added after PDT, we excluded it from further study in MCF-7 cells.
Acute glycolysis inhibition following PDT compromises MCF-7 long-term survival. Following acute (24 h) exposure to glycolysis inhibitors, clonogenic assays of surviving cells were used to test MCF-7 long-term survival and proliferative ability. Comparing PDT with corresponding dark-treated cells, there were 1.9-fold fewer colonies in no-drug controls, 2.6-fold fewer colonies in acute 2DG-treated cells, and 10.1-fold fewer colonies in acute lonidamine treated cells ( Figure 2E and F) . 
Mechanisms of glycolysis inhibition-augmented PDT cytotoxicity.
We examined the time-courses of: cell death, ROS generation and ATP depletion for up to 4.5 h after PDT.
Cell death. In the dark, all conditions demonstrated a consistent and low (o7%) cytotoxicity, with 2DG or lonidamine being significantly more cytotoxic than the no-inhibitor control ( Figure 3A) . Within 90 min of PDT, lonidamine significantly increased percentage cell death to 20%. Cell death was maintained at this level until the end of the observation period (270 min). By contrast, PDT followed by 2DG incubation demonstrated less cell death than the control at 90 min, although death increased to above control levels by 270 min ( Figure 3A) . Apoptosis was assessed at 2 h and 4 h post-PDT (or darkness, for controls) using Annexin V-FITC/PI FACS. For this experiment, PDT was performed at 15 J cm À 2 to improve the annexin V detection rate for statistical analysis. Cell death was associated with increased apoptosis for PDT with lonidamine, but not for PDT with 2DG, suggesting distinct initial cell death mechanisms ( Figure 3B ).
Reactive oxygen species levels. Reactive oxygen species levels were assayed every 30 min from immediately after PDT to 270 min later, using a fluorogenic probe sensitive to most ROS species (DCFHDA) or to superoxides (DHE) (Figure 3C and D) . At each time point and with either probe, ROS levels generally followed the order: lonidamine4control42DG (Figure 3C and D) . Unexpectedly, ROS levels in the presence of 2DG were consistently much lower than no-drug controls, which was counterintuitive considering how well 2DG enhanced PDT cytotoxicity (Figure 2) . We wondered if the apparent low ROS levels with 2DG could be an artefactual consequence of lower probe uptake or impaired processing by intracellular esterases, unrelated to the actual ROS levels. We used the ROS-insensitive positive control probe, carboxy-DCFDA (10 mM), to monitor probe accumulation during 30 min, and found this was 2.6-fold lower in the presence of 2DG, suggesting that ROS levels with 2DG (in Figure 3C) likely did exceed no-drug control levels.
ATP levels. Glycolysis inhibitors caused rapid (within 30 min) and stable (to 2 h after application) depletion of ATP levels compared with ALA-only controls ( Figure 4A ). The ATP concentration always followed the sequence control4lonidamine42DG. Moreover, ATP levels following PDT were always lower than corresponding dark controls ( Figure 4A ).
Glycolysis inhibition potentiates PDT cytotoxicity selectively in cancer cells. Photodynamic therapy cytotoxicity was examined in normal primary HMEC, with inhibitors added 15 min before 10 J cm À 2 PDT and maintained for 24 h. In contrast to the results with MCF-7 cells (Figure 2A and C), each inhibitor caused o10% cell death in HMEC following PDT ( Figure 5A ), while dark toxicity was similar to that in MCF-7 cells ( Figure 1A ; Figure 2C ). Photodynamic therapy showed a (non-significant) trend of reducing the number of live HMEC compared with dark controls ( Figure 5B) . However, the magnitude of this decrease was much smaller than that observed with MCF-7 cells ( Figure 2D ). 
DISCUSSION
Increased metabolism and a shift towards aerobic glycolysis are hallmarks of cancer, making this pathway an attractive clinical target. Previous work has demonstrated that 2DG (Noodt et al, 1998; Dahle et al, 2001; Kirveliene et al, 2003) , and lonidamine (Shevchuk et al, 1996) can potentiate PDT cytotoxicity. However, this is the first study to directly compare three clinical glycolysis inhibitors, their optimum application times and light doses. We show that acute glycolysis inhibition by oLD 10 concentrations of 2DG or lonidamine, during or just after ALA PDT, results in more than a three-fold increase in MCF-7 cytotoxicity after 24 h. By contrast, 12 mM 3Br only potentiated PDT cytotoxicity when coadministered with ALA, although it depleted ATP levels to a similar extent as 300 mM lonidamine (Supplementary Figure S2) , suggesting that ATP depletion by itself is insufficient to increase PDT cytotoxicity. On a molar basis, lonidamine was more effective than 2DG at potentiating PDT.
Although lonidamine is tolerated at 300 mM in vitro, it has only been tested systemically in humans at up to 127 mM (Gatzemeier et al, 1991) . Despite this, high concentrations of 2DG or lonidamine may prove clinically relevant for topical PDT (e.g., 300 mM 2DG is tolerated topically (Kern et al, 1982) ).
The improved PDT cytotoxicity with 2DG or lonidamine is selective towards MCF-7 breast cancer cells, compared with HMEC primary breast cells, and is optimal at low light doses (5-10Jcm
À 2 ). Glycolysis inhibition plus PDT is cytotoxic rather than cytostatic, as a continued decrease in cell viability was seen after removal of glycolysis inhibitors, with up to a 10-fold increase in cytotoxicity compared with dark controls seen in 9-day clonogenic assays.
Although the extent of MCF-7 cell death was similar with 2DG or lonidamine 24 h after PDT, differences were apparent in their initial PDT cytotoxicity that suggest distinct cell death mechanisms. Lonidamine demonstrated initially higher levels of PDT-induced ROS, a faster onset of cytotoxicity, and significant apoptosis compared with 2DG ( Figure 3 ). By contrast, 2DG depleted ATP levels more than lonidamine (Figure 4 ) and had a slower onset of PDT cytotoxicity, beginning around 4 h after PDT ( Figure 3A) , which was probably necrotic, as it was not associated with elevated apoptosis ( Figure 3B ). ATP is required to initiate apoptosis (Reubold and Eschenburg, 2012) , and in our experiments 2DG perhaps depletes ATP below this critical threshold. A previous study (Oberdanner et al, 2002) similarly demonstrated that inhibiting glycolysis (using glucose-free media) prevented PDT-induced apoptosis.
To facilitate translation of this work, we deliberately chose clinically validated (phase II/III) glycolysis inhibitors, for which the posology and safety characteristics are already known, and one of the most popular clinically licensed photosensitisers (Brawer, 2005; Morton et al, 2008; Dwarakanath, 2009) . By using existing systemic drug regimens, we propose that tumours could immediately be treated by conventional PDT, followed by acute 24 h glycolysis inhibition, the combination therapy being more effective than either treatment alone. In the longer term, depending on successful clinical testing, we propose that higher doses of glycolysis inhibitors, similar to those we use here, could be applied locally and topically for improved treatment of skin cancers and pre-cancers, for which PDT is already recommended (Morton et al, 2008) . This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons AttributionNonCommercial-Share Alike 3.0 Unported License.
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